Background: Generic drugs can contribute to access to treatment for HIV-infected patients. However quality and safety remains an issue of concern. Therefore, we evaluated minimal plasma concentrations and short-term safety of a generic lopinavir/ritonavir 200/50 mg tablet formulation. Methods: In a single-centre prospective pilot study, patients receiving protease-inhibitor-based antiretroviral treatment were switched to a generic lopinavir/ritonavir tablet at the standard dose (400/100 mg twice daily). Minimum drug concentrations (C min ) of lopinavir and ritonavir were performed before switching (in 16 patients who were on Kaletra® soft-gel capsules) and after 4 weeks (in all patients). Plasma levels of lopinavir and ritonavir were determined by a validated HPLC method. Either the Wilcoxon signed-rank or Mann-Whitney U test was used to compare the groups.
The availability of generic products is an important factor in the global scale-up of antiretroviral treatment (ART) for HIV-infected patients [1] . Data collected by the Global Price Reporting Mechanism showed that 96% of generic antiretrovirals (ARVs) used were for first-line ART, with generic products accounting for only 7% of all second-line ARVs being used [2, 3] .
At present, approximately 97% of adults and children treated with ARVs in low-and middle-income countries are receiving first-line therapy [4] . It is estimated, however, that 6-10% of the patients per year will need second-line ART because of first-line treatment failure [5] . The average price of second-line regimens can cost up to 5× more compared with the first-line regimens [3] . This is not only a result of higher production costs, but also because of the lack of competition with limited World Health Organization (WHO) pre-qualified generic second-line ARVs [4] .
Lopinavir/ritonavir is the leading protease inhibitor used for second-line ART in patients failing first-line non-nucleoside reverse transcriptase inhibitor-based regimens. It has advantages over other ritonavirboosted protease inhibitors for its combined lopinavir and ritonavir formulation in addition to its heat However, generic lopinavir/ritonavir is not widely used because of concerns about quality and little or no available data [6] .
Short communication
Here, we conducted an independent pilot study in Thai HIV type-1 (HIV-1)-infected individuals, to evaluate the minimum drug concentration (C min ) and shortterm safety of a generic lopinavir/ritonavir 200/50 mg tablet formulation.
Methods

Patients
Patients receiving protease-inhibitor-based ART for ≥3 months with plasma viral load <50 copies/ml and no history of protease inhibitor failure or active AIDSdefining illness were included. The generic lopinavir/ ritonavir used in this study was manufactured by Matrix Laboratories (Secunderabad, India) and pre-qualified by the WHO; however, no bioavailability, efficacy and safety data were available in the public domain. The primary objective of the investigation was to evaluate the C min of generic lopinavir/ritonavir in a convenience sample of HIV-1-infected Thai patients to provide previously undefined preliminary data on exposures of this product in this population. Secondarily, in a subset of this population, we provide an intrapatient comparison of lopinavir/ritonavir C mins between Kaletra ® SGC and the generic tablets.
At the start of the study (n=37) the protease inhibitors of recent regimens were replaced by a generic lopinavir/ ritonavir tablet (200/50 mg) formulation at the standard 400/100 mg twice-daily dosing for all patients. The nucleoside reverse transcriptase inhibitor (NRTI) backbone remained unchanged. After 4 weeks, all patients underwent blood draw for therapeutic drug monitoring (TDM) at 11-12 h after drug intake to measure the C min . For 16 patients who were already on Kaletra ® SGC at baseline, TDM was also performed before switching to the generic tablet. The research was conducted in accordance with the Declaration of Helsinki and national and institutional standards. Informed consent was obtained from all patients and the study was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Plasma levels of lopinavir and ritonavir were determined by a validated HPLC method [7] , with a lower limit of quantification of 0.1 mg/l for lopinavir and 0.045 mg/l for ritonavir.
Safety laboratory assessments were done at week 0 and week 4 (consisting of liver aminotransferase, lipid profile, glucose, creatinine and blood cell count). Adverse events were reported throughout the 4-week study period and graded according to the DAIDS toxicity table.
Time of food intake with last dose and product storage practice was documented to assess their effects on drug levels. No particular advice considering food intake was given by the physician.
Statistical analyses
Medians and interquartile ranges (IQRs) were calculated and a Wilcoxon signed-rank test used to compare the lopinavir plasma concentrations of Kaletra ® SGC to the generic lopinavir/ritonavir tablets within the same patients. The Mann-Whitney U test was used when between-patient calculations were performed. As a measure of interpatient variability, the coefficient of variance was calculated as the sd divided by the mean. An a priori power calculation was not performed as a convenience sample was used to evaluate both the primary and secondary objectives.
Results
A total of 37 patients (18 female) were included in the study, with a median (IQR) age of 41 years (36-45.4). The median (IQR) weight was 58.5 kg (51.9-66.5). Overall, 16 patients were already receiving Kaletra ® SGC before the start of the study ( Generic lopinavir/ritonavir tenofovir/lamivudine, 6 had tenofovir/emtricitabine, 3 had didanosine/lamivudine, 2 had tenofovir/zidovudine and 1 had tenofovir/stavudine. Two patients stopped their study medications prematurely, one because of nausea and vomiting (on day 1), and one because of difficulty in swallowing the lopinavir/ritonavir tablet (on day 3). These patients were on ritonavir-boosted saquinavir and indinavir, respectively at time of enrolment. Of the remaining 35 patients who were followed to week 4, their median (IQR) lopinavir C min was 7.2 mg/l (5.8-8.3), with a mean time of sample collection of 11.5 h (0.17) after the last dose. No patients had subtherapeutic levels <1.0 mg/l or even <4.0 mg/l (considered adequate for patients with protease inhibitor resistance). None of the patients were sampled after 13 h of drugs intake or earlier than 11 h. The coefficient of variance was 25%. The median (IQR) ritonavir C min was 0.43 mg/l (0.30-0.63) with a coefficient of variance of 49%. There was no significant difference in lopinavir plasma levels for the patients who had tenofovir in their backbone compared with those who did not.
Overall, 17 (46%) patients took their product with food. The median (IQR) C min was 6.9 mg/l (6.7-8.7) for this group, compared with 7.3 mg/l (5.9-8.0) for the 18 patients who took their products without food (P=0.680). Three patients stored lopinavir/ritonavir in the refrigerator (their lopinavir levels were 4.32 mg/l, 11.38 mg/l and 6.68 mg/l, respectively).
Lopinavir levels were compared in 16 patients before and after switching from Kaletra ® to generic lopinavir/ ritonavir (Table 2) . These patients had been on Kaletra ® for a median (range) time of 73 weeks (3-263) prior to enrolment. No significant difference of lopinavir C min levels was found between the two formulations; however, the investigation was not powered enough to show a difference. The coefficient of variance for the generic product was 25%, whereas it was 54% for Kaletra ® , suggesting better stability of the generic tablet formulation compared with the SGC. The median (IQR) C min of generic ritonavir was significantly higher than that of Kaletra ® (P=0.019).
One patient prematurely discontinued the study because of gastrointestinal intolerance and 12 had grade 1-2 gastrointestinal complaints with 9 of these 12 resolving in 4 weeks. Of patients who were taking Kaletra ® SGC at baseline, four reported new gastrointestinal complaints after switching to the generic product.
No grade 3 or 4 events, which were at least possibly related to the study drugs, were reported.
Discussion
To our knowledge this is the first independent study reporting plasma concentrations of generic lopinavir/ ritonavir in HIV-1-infected patients. We found generic lopinavir/ritonavir to have excellent plasma concentrations and stability, independent of food intake. The lopinavir C min levels were similar to those of Kaletra ® SGC in our study. By contrast, the ritonavir levels of the generic product were significantly higher than those of the Kaletra ® formulation, possibly leading to more gastrointestinal toxicity. Because of the small sample size, conclusions should be taken with caution considering the large variability of ritonavir levels.
The higher ritonavir levels are most likely explained by the difference in formulation used. In the healthy volunteer study of Klein et al. [8] , an increase in ritonavir bioavailability of 19-35% was reported for area under the curve and maximum concentration for the tablet compared to the SGC formulations (both Abbott Laboratories products). There was also a trend towards higher lopinavir for the tablet formulation, which was, as the C min in our study, less profound than that of ritonavir (18-23% increase) [8] . We were not able to study the generic lopinavir/ritonavir tablet against the branded tablet formulation, Aluvia ® , as this product was not imported into Thailand by the manufacturer after the Thai government adopted compulsory licensing policy for lopinavir/ritonavir [9] . The median C mins for both the generic lopinavir/ritonavir tablet and Kaletra ® SGC formulations were very high and near the level of 8.0 mg/l, which is associated with lipid increases [10] . Similar high concentrations of other protease inhibitors Time of sample collection after last intake of lopinavir (LPV) and ritonavir (RTV). Time of collection was the same for both LPV and RTV. C min , minimum drug concentration; IQR, interquartile range; NA, not applicable; SGC, soft-gel capsule.
have been found in Thai populations [11] , and might indicate that dose adjustments are warranted in particular populations, especially Asians.
This study is subject to some limitations. First, the study design is a single TDM C min measurement and therefore unable to evaluate the detailed parameters of drug exposure required for pharmacokinetic study. Second, this is a cross-sectional study, therefore there is no data related to the long-term adverse events of LPV, such as lipid toxicity. Third, the sample for comparison only contained 16 patients and was therefore not powered enough to detect potential differences between the two formulations. Indeed, by using the means and sd available from our study, we found only a 19% power to detect a significant difference between the groups with the current sample size. However, this has not been the primary objective of our study.
In summary, concentrations of lopinavir/ritonavir from patients taking generic tablets provides similar exposures as that of Kaletra ® SGC, suggesting similar safety and efficacy in Thai patients. In Thailand, where the heat-stable branded tablet lopinavir/ritonavir is not available, these results are of great importance. We are collecting long-term safety and efficacy data to assess the potency and tolerability of generic lopinavir/ritonavir. These data support the effort in scaling up secondline treatment in middle-and low-income countries by using generic products to further reduce prices.
